Cutaneous squamous cell carcinomas (SCCs) account for up to 10,000 deaths annually in the United States. Most of the more than 700,000 SCCs diagnosed are cured by excision with clear margins; however, metastasis can occur despite seemingly adequate treatment in some cases. Immune-suppressed organ transplant recipients are 60 to 100 times more likely to develop SCC than immune-competent individuals. Transplant-associated SCCs occur more frequently and behave more aggressively, showing higher risk of recurrence and metastasis. This article identifies a potential role for interleukin-22 in driving SCC proliferation, particularly in solid organ transplant recipients taking cyclosporine.
Keywords: Cyclosporine; IL-22; Immunosuppression; Nonmelanoma skin cancer; Organ transplant recipient; Squamous cell carcinoma; Transplant-associated squamous cell carcinoma.
Copyright © 2016 Elsevier Inc. All rights reserved.